Post by icemandios on Aug 29, 2016 23:48:39 GMT
And in the headlines of the PR, we find:
Q4'16 revenue $532.2 million increased 6% in constant currency from the prior year period
FY'16 revenue of $1.85 billion increased 6% in constant currency from the prior year period
Catalent's proprietary OptiShell™ softgel technology has been selected for use in OPKO
Health's NDA for RAYALDEE® and has been approved by the U.S. FDA
Announced the launch of our FastChain™ service, for greater speed, flexibility and efficiency in the management and distribution of global clinical trial supplies
Full Text of the PR
Full Text of the 10-K
Q4'16 revenue $532.2 million increased 6% in constant currency from the prior year period
FY'16 revenue of $1.85 billion increased 6% in constant currency from the prior year period
Catalent's proprietary OptiShell™ softgel technology has been selected for use in OPKO
Health's NDA for RAYALDEE® and has been approved by the U.S. FDA
Announced the launch of our FastChain™ service, for greater speed, flexibility and efficiency in the management and distribution of global clinical trial supplies
Full Text of the PR
Full Text of the 10-K